Future Ventures

Venture Capital Exempt reporting adviser

Legal name: Future Ventures Management, LLC

Los Altos, CA Website LinkedIn X

AUM

$6.6B
Private fund assets

Private funds

16
Venture Capital 16

Private fund assets

$6.6B
Gross asset value

Employees

—

Last Form D raise

May 2024
Most recent fund filing

From SEC Form ADV filing (filed Mar 31, 2026). View on SEC

Investment focus

As listed in industry directories; may be out of date.

Stages
Series A
Geographies
USA

People(2)

Owners and executive officers named on the firm's SEC Form ADV.

M
Maryanna Saenko
Managing Member (future Ventures GP, LLC)
Source: SEC Form ADV
S
Stephen Jurvetson
Managing Director
Source: SEC Form ADV

Funds(16)

Private funds reported on Form ADV, with amounts raised from the funds' SEC Form D filings.

FundTypeGross assetsRaised (Form D)InvestorsLast Form DRecency
Future Ventures AI, LLCVenture Capital$1.1B$168.9M68May 2024Cold
Future Ventures AI II, LLCVenture Capital$151.8M$168.9M68May 2024Cold
Future Ventures III, L.P.Venture Capital$374.8M——Dec 2022Cold
Future Ventures IV, L.P.Venture Capital$228.9M——Dec 2022Cold
Future Ventures Side Fund III, L.P.Venture Capital$22.1M——Dec 2022Cold
Future Ventures Side Fund IV, L.P.Venture Capital$12.1M——Dec 2022Cold
Future Ventures Final Frontier Fund III, LLCVenture Capital$320.0M$53.3M35Jun 2022Cold
Future Ventures Commonwealth Fusion Fund II, LLCVenture Capital$802.1M$60.0M50Mar 2022Cold
Future Ventures Commonwealth Fusion Fund, LLCVenture Capital$88.3M$60.0M50Mar 2022Cold
Future Ventures Commonwealth Fusion Fund II (blocker), LLCVenture Capital$1.9M$60.0M50Mar 2022Cold
Future Ventures Final Frontier Fund II, LLCVenture Capital$802.1M$80.3M54Mar 2021Cold
Future Ventures Side Fund II, L.P.Venture Capital$18.8M$10.0M4Jan 2021Cold
Future Ventures II, L.P.Venture Capital$314.0M$200.0M110Jan 2021Cold
Future Ventures Final Frontier Fund, LLCVenture Capital$1.6B$100.3M47Aug 2020Cold
Future Ventures, L.PVenture Capital$817.7M$200.0M100Feb 2019Cold

Board seats(1)

Companies whose SEC Form D filings name one of this firm's people as a director, matched by name and office ZIP code.

Cambrian BioPharma
BiotechnologyNew York, NYDirector: Maryanna Saenko
$272.2M raised
Since Jan 2025
SEC Form D

Shares boards with

Firms whose people sit on the same company boards.

Anthos Capital
Asset Manager
1 shared

Regulatory identifiers

CRD number
301700
SEC file number
802-117023

Sources